Clinical trial NCT05567328: Validation of the New Vibration-guided FibroScan Examination
Official title: Validation of the New Vibration-guided FibroScan Examination
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Diseases
Keywords: FibroScan
Vibration Control Transient Elastography
Vibration Guided Transient Elastography
Liver Stiffness Measurement
VCTE
VGTE
Lead sponsor: Echosens
Sponsor class: INDUSTRY
First posted: 2022-10-05
Enrollment: 270
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This is an European, prospective, interventional, multicenter clinical investigation that will take place in 2 French sites. 100 adults patients will be included. The study objective is to compare the applicability between the Research FibroScan and the reference FibroScan examination performed on the liver.

Detailed description: Chronic liver disease (CLD) is a silent disease that can progress to life-threatening conditions. Hepatitis B (HBV) and C (HCV) viruses, alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are the main causes of chronic liver inflammation.

CLDs represent a major public health burden, with global estimates showing around a rate of 2 million deaths per year, including 1 million from complications of cirrhosis and 1 million from viral hepatitis and hepatocellular carcinoma. About 75 million people are diagnosed with alcohol use disorders and are at risk of developing alcohol-related liver disease. About 2 billion adults are obese or overweight and more than 400 million suffer from diabetes; both of which are risk factors for the development of NAFLD and HCC.

NAFLD is currently the leading cause of CLD worldwide with a reported worldwide prevalence of 25% in adults. Early identification among NAFLD patients with non-alcoholic steatohepatatis (NASH) and advanced fibrosis is particularly important as they are at high risk of developing liver complications. The main difficulty in diagnosing NASH patients is related to their symptomatology, which is not always clinically useful because it is not specific. Therefore a screening for advanced stage of NAFLD is recommended in patient at high risk such patients with type 2 diabetes or obesity.

Liver fibrosis is known to be a major prognostic predictor of hepatic and overall mortality in patients with CLD. Therefore, early diagnosis of liver fibrosis is crucial in asymptomatic individuals.

Liver biopsy (LB) is the gold standard diagnostic test for the evaluation of patients with CLD. However, it is difficult to use it as a screening tool given the large number of patients with NAFLD.

The development of non-invasive and broadly applicable screening tools for the assessment of liver fibrosis appears to be a major public health opportunity.

Among the non-invasive tools available, the FibroScan (Echosens™, Paris, France) has proven to be a useful tool for diagnosing fibrosis and steatosis in patients with CLD. FibroScan is a device based on Vibration-Controlled Transient Elastography (VCTE™) technology that measures Liver Stiffness Elasticity (LSM) to assess fibrosis and Controlled Attenuation Parameter (CAP) to assess steatosis.

In this context, Echosens aims to develop a new technology called "Vibration-Guided Transient Elastography (VGTE)" which is an original method that will help FibroScan operators to localize an optimal region of interest for stiffness measurement in a simple and reliable way.

Eligibility criteria: Inclusion Criteria:

* Adult patients (age \> = 18 years old) followed for a liver disease; a suspicion of liver disease or for consequences of liver disease, all etiologies combined
* Patient must be able to give written informed consent
* Patient affiliated to a social security system

Exclusion Criteria:

* Vulnerable patient
* Patients with ascites

Primary outcomes:
measure: Difference of patient percentage having a successful examination between the novel and the reference FibroScan examination
timeFrame: 17 months
Secondary outcomes:
measure: Difference of success rate between the novel and the reference FibroScan examination
timeFrame: 17 months
measure: Difference between the initial localization durations required for the novel and the reference FibroScan examination.
timeFrame: 17 months
measure: Difference between the examination durations required for the novel and the reference examination based on liver stiffness measurements.
timeFrame: 17 months
measure: Difference between the examination durations required for the novel and the reference examination based on CAP measurements.
timeFrame: 17 months
measure: Intraclass Correlation Coefficient (ICC) between novel and reference FibroScan examinations
timeFrame: 17 months
measure: Evaluation of the operator perception between the novel and reference examination
timeFrame: 17 months
measure: Evaluation of the patient perception between the novel and reference examination
timeFrame: 17 months
measure: ICC between the two novel FibroScan examinations and the two reference FibroScan examinations and coefficient of repeatability of stiffness and CAP examination performed by the same operator, on the same patient the same day.
timeFrame: 17 months
measure: ICC between novel and reference FibroScan examinations based on the operator's level expertise and coefficient of reproducibility of stiffness and CAP examination performed by the 2 different operators, on the same patient the same day.
timeFrame: 17 months
Other outcomes:
Locations:
city: Clichy
country: France
facility: Hôpital Beaujon
city: Lyon
country: France
facility: Hospices Civils de Lyon - Lyon Sud
city: Nancy
country: France
facility: CHU de Nancy
Study officials:
References: